WAYNE, Pa.--(BUSINESS WIRE)--Oct. 29, 2018--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
technologies for critical care and surgery, is proud to announce the
Arrow AC3 Optimus Intra-Aortic Balloon Pump, has been selected as the
bronze winner in the cardiovascular device category of the 20th
annual Medical Design Excellence Awards competition. The 2018 winning
products were announced at the MDEA ceremony held at the Jacob K. Javits
Convention Center in New York.
The AC3 Optimus IABP helps a weakened heart pump blood and can deliver
IABP therapy to a broad range of patients, even those not previously
considered candidates for IABP therapy. Clinicians may use the pump on
patients with the most arrhythmias or with heart rates as high as 200
beats per minute.1, 2 In IABP therapy, a physician inserts an
intra-aortic balloon catheter into an artery, and using x-ray or
imaging, advances the catheter into the aorta. An IABP console,
connected to the catheter, controls the inflation and deflation of the
balloon.
“We are proud to receive this honor. As innovators in intra-aortic
balloon pumping technology, we have made it our commitment to provide a
solution that advances the performance and reliability of automated
therapy," said Stew Strong, President and General Manager of the
Interventional Division at Teleflex. "This award is a testament to our
passion and dedication to providing purpose-driven innovation to improve
the health and quality of people’s lives.”
The MDEA competition is the medical technology industry’s premier design
competition, committed to searching for the world’s highest caliber
medical devices, products, systems or packaging available on the market.
Products were judged based on design and engineering innovation,
function and user-related innovation, patient benefits, business
benefits, and overall benefit to the healthcare system.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com
Teleflex is the home of Arrow® Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch®, UroLift® and Weck® – trusted brands united by a common sense of
purpose. ®
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, AC3 Optimus, Deknatel, Hudson
RCI, LMA, UroLift, Pilling, Rusch and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
©2018 Teleflex Incorporated.All
rights reserved. MC-004336
References:
-
Schreuder J, Castiglioni A, Donelli A, et al. Automatic intraaortic
balloon pump timing using an intra beat dicrotic notch prediction
algorithm. Ann Thorac Surg. 2005;79(3):1017-1022. Study
sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of
the study sponsor. Co-authors J. Bovelander, R. Hanania, and P. Hanlon
are current or former employees of the study sponsor.
-
Donelli A, Jansen JRC, Hoeksel B, et. al. Performance of
a real-time dicrotic notch detection and prediction algorithm
in arrhytmic human aortic pressure signals. J Clin
Monit. 2002;17(3-4):181-185. Study sponsored by Teleflex. Dr.
Schreuder was formerly a paid consultant of the study sponsor.
Co-authors J. Bovelander and R. Hanania are current or former
employees of the study sponsor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005039/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836